Meeting
2011 ASCO Annual Meeting
Gemcitabine plus oxaliplatin (GemOx) in advanced hepatocellular carcinoma (HCC): A multicenter study of over 200 patients.
Authors
N. Williet
Service de Cancérologie Digestive HEGP, Paris, France
N. Williet , A. Zaanan , M. Hebbar , V. Boige , L. Fartoux , T. Mansourbakht , O. Dubreuil , O. Rosmorduc , F. Bonnetain , J. Taïeb
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Citation
J Clin Oncol 29: 2011 (suppl; abstr 4033)
Abstract #
4033
Poster Bd #
23A
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase II study of gemcitabine with oxaliplatin (GEMOX) in heavily treated patients with advanced hepatocellular carcinoma after failure of sorafenib treatment (PEACH).
First Author: Choong-kun Lee
Poster
2021 ASCO Annual Meeting
Comparative effectiveness of sorafenib, lenvatinib, and nivolumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis treated at VA Medical Centers.
First Author: William Joseph Chapin
Poster
2021 Gastrointestinal Cancers Symposium
Efficacy and safety of 5-fluorouracil (5-FU) / levofolinate / irinotecan (FOLFIRI) for previously treated advanced pancreatic cancer (APC).
First Author: Hiromichi Shirasu
Poster
2017 Gastrointestinal Cancers Symposium
Sorafenib treatment for advanced hepatocellular carcinoma: Effectiveness, safety, and controversial points.
First Author: Takayoshi Oikawa